Metformin and the gastrointestinal tract
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
Metformin is an effective agent with a good safety profile that is widely used as a first-line treatment for type 2 diabetes, yet its mechanisms of action and variability in terms of efficacy and side effects remain poorly understood. Although the liver is recognised as a major site of metformin pharmacodynamics, recent evidence also implicates the gut as an important site of action. Metformin has a number of actions within the gut. It increases intestinal glucose uptake and lactate production, increases GLP-1 concentrations and the bile acid pool within the intestine, and alters the microbiome. A novel delayed-release preparation of metformin has recently been shown to improve glycaemic control to a similar extent to immediate-release metformin, but with less systemic exposure. We believe that metformin response and tolerance is intrinsically linked with the gut. This review examines the passage of metformin through the gut, and how this can affect the efficacy of metformin treatment in the individual, and contribute to the side effects associated with metformin intolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of these minor side effects include gastrointestinal discomfort such as abdominal or stomach pain, early satiety, decreased appetite, and diarrhea, which usually subside after one or two weeks of use (McCreight et al. 2016).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as McCreight et al. 2016
Experimental — accuracy not yet measuredIn the citing paper
“As in most drugs, minor side effects occur with metformin, but it is important to understand whether they reveal anything about the mechanism of action of this drug.”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as McCreight et al. 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762 · cited 2×
“Although these two studies differ in terms of the changes they identified, a common finding was a reduction in butyrate-producing bacteria and an increase in opportunistic pathogens [78, 81].”
BackgroundResultCross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511 · cited 1×
“…(resulting in an increase in A. muciniphila ) or direct treatment with A. muciniphila has been reported to improve metabolic disorders, possibly by increasing endocannabinoids, which reduce inflammation, modify gut peptide secretion and improve the thickness of the gut mucous barrier [82].”
BackgroundGut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115 · cited 1×
“2) [79].”
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · cited 1×
“The increase in the bile acid pool may then stimulate TGR5 bile acid receptors on the L cell [62, 67], causing an increase in GLP-1 secretion via mitochondrial oxidative phosphorylation and calcium influx [67].”
BackgroundMolecular imaging of cancer with positron emission tomography
Gambhir, S. S. (2002) · Nature Reviews Cancer · doi:10.1038/nrc882 · Cited by 1,656 · cited 1×
“PET-CT is commonly used for the diagnosis, staging and monitoring of the response to treatment, of certain cancers [32].”
MethodShin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550 · cited 2×
“Administration of A. muciniphila to mice receiving a high-fat diet improved glucose tolerance [86], suggesting that the effect of metformin on abundance of this species within in the microbiome may indirectly contribute to the glucose-lowering effect of metformin.”
BackgroundClinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 1×
“phosphate dehydrogenase, reducing the conversion of cytosolic lactate into pyruvate [42].”
BackgroundHuman Gut Microbiota Changes Reveal the Progression of Glucose Intolerance
Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., Chen, Y., & Ji, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071108 · Cited by 946
Microbiota and diabetes: an evolving relationship
Tilg, H., & Moschen, A. R. (2014) · Gut · doi:10.1136/gutjnl-2014-306928 · Cited by 853 · cited 1×
“Although these two studies differ in terms of the changes they identified, a common finding was a reduction in butyrate-producing bacteria and an increase in opportunistic pathogens [78, 81].”
ResultTraditional Plant Medicines as Treatments for Diabetes
Bailey, C. J., & Day, C. (1989) · Diabetes Care · doi:10.2337/diacare.12.8.553 · Cited by 832 · cited 1×
“Its origins can be traced to Galega officinalis, also known as French lilac or goat ’ s rue [1].”
BackgroundSelf-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
Gorboulev, V., Schürmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., et al. (2012) · Diabetes · doi:10.2337/db11-1029 · Cited by 687
Clinical Pharmacokinetics of Metformin
Scheen, A. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630050-00003 · Cited by 636
Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review
Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014) · JAMA · doi:10.1001/jama.2014.15298 · Cited by 601
Self-citationThe SLC22 drug transporter family
Koepsell, H., & Endou, H. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1089-9 · Cited by 525 · cited 2×
“OCT2 is expressed mainly in the kidney and is partly responsible for the renal excretion of metformin [18].”
BackgroundMetformin kinetics in healthy subjects and in patients with diabetes mellitus.
Tucker, G., Casey, C., Phillips, P., Connor, H., Ward, J., & Woods, H. (1981) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1981.tb01206.x · Cited by 497 · cited 3×
“Metformin uptake is saturable and dose-dependent [10, 16], consistent with the theory that it is mostly transporter-dependent.”
BackgroundAccumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418
Self-citationThe Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing
Röder, P. V., Geillinger, K. E., Zietek, T. S., Thorens, B., Koepsell, H., & Daniel, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089977 · Cited by 408 · cited 1×
“The mechanism whereby metformin increases gut glucose uptake and utilisation remains unclear [36 – 40].”
BackgroundLactic Acidosis in Patients with Diabetes Treated with Metformin
Misbin, R. I., Green, L., Stadel, B. V., Gueriguian, J. L., Gubbi, A., & Fleming, G. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801223380415 · Cited by 403 · cited 2×
“Several studies have attempted to localise the lactate production associated with metformin treatment [44 – 49].”
BackgroundMetformin Activates a Duodenal Ampk-Dependent Pathway to Lower Hepatic Glucose Production in Rats
Duca, F. A., Côté, C. D., Rasmussen, B. A., Zadeh-Tahmasebi, M., Rutter, G. A., Filippi, B. M., & Lam, T. K. T. (2015) · Nature Medicine · doi:10.1038/nm.3787 · Cited by 402 · cited 2×
“However, when metformin was infused into the hepatic portal vein, no increase in the glucose infusion rate was required, and there was no decrease in he-patic glucose production over the same timeframe [70].”
BackgroundEffect of Metformin on Metabolic Improvement and Gut Microbiota
Lee, H., & Ko, G. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01357-14 · Cited by 385 · cited 1×
“Metformin alters the microbiome in both mice and humans, causing an overall decrease in the bacterial diversity of the mouse microbiome, which contrasts with the effect of a high-fat diet [85, 86].”
BackgroundMetformin: its botanical background
Bailey, C., & Day, C. (2004) · Practical Diabetes International · doi:10.1002/pdi.606 · Cited by 353 · cited 1×
“In the early 20th century it was noted to lower blood glucose concentrations in animals, but it was not until the 1950s that Jean Sterne studied dimethylbiguanide and subsequently developed ‘ Glucophage ’ [2].”
BackgroundSelf-citationBuse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325 · cited 2×
“These findings, and recent evidence that a delayed-release formulation of metformin with minimal systemic absorption retains its glucose-lowering efficacy [15], suggest that the glucose-lowering effects of metformin are strongly influenced by effects on the gut.”
BackgroundMannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S., Nicholls, A. W., Baker, D., Van Horn, S., Thomas, E., Rajpal, D., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 282 · cited 1×
“The increase in the bile acid pool may then stimulate TGR5 bile acid receptors on the L cell [62, 67], causing an increase in GLP-1 secretion via mitochondrial oxidative phosphorylation and calcium influx [67].”
BackgroundDujic, T., Zhou, K., Donnelly, L. A., Tavendale, R., Palmer, C. N. A., & Pearson, E. R. (2015) · Diabetes · doi:10.2337/db14-1388 · Cited by 278 · cited 4×
“This increased to an over fourfold increase in the odds for intolerance in patients with two reduced function OCT1 alleles who were also treated with OCT1-inhibiting drugs ( p 0.001) [7].”
BackgroundInfluentialSelf-citationBailey, C. J., Wilcock, C., & Scarpello, J. H. B. (2008) · Diabetologia · doi:10.1007/s00125-008-1053-5 · Cited by 275
Self-citationIdentification and Characterization of a Novel Monoamine Transporter in the Human Brain
Engel, K., Zhou, M., & Wang, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407913200 · Cited by 267 · cited 1×
“PMAT was originally identified as a monoamine transporter from the equilibrative nucleoside transporter (ENT) family, found predominantly in the brain and central nervous system [23, 24].”
BackgroundDrug specificity and intestinal membrane localization of human organic cation transporters (OCT)
Müller, J., Lips, K. S., Metzner, L., Neubert, R. H. H., Koepsell, H., & Brandsch, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.011 · Cited by 262 · cited 1×
“Although initial reports localised OCT1 to the basolateral membrane [19], more recent reports place OCT1 on the apical surface of intestinal epithelial cells [20, 21].”
ResultGut Microbiota and Metabolic Disorders
Hur, K. Y., & Lee, M.-S. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.3.198 · Cited by 259
Christensen, M. M. H., Brasch-Andersen, C., Green, H., Nielsen, F., Damkier, P., Beck-Nielsen, H., & Brosen, K. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c0010 · Cited by 259 · cited 1×
“An initial report that OCT1 variants altered the glycaemic response to metformin in a clinical trial [28] was not confirmed in a recent re-analysis that took account of the baseline HbA 1c level [29].”
BackgroundZhou, M., Xia, L., & Wang, J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015495 · Cited by 251 · cited 2×
“PMAT is localised to the tips of the mucosal epithelial layer, suggesting that PMAT has an integral role in metformin uptake [25].”
BackgroundMechanism of metformin action in non-insulin-dependent diabetes
Jackson, R. A., Hawa, M. I., Jaspan, J. B., Sim, B. M., DiSilvio, L., Featherbe, D., & Kurtz, A. B. (1987) · Diabetes · doi:10.2337/diab.36.5.632 · Cited by 202
High and typical 18F-FDG bowel uptake in patients treated with metformin
Gontier, E., Fourme, E., Wartski, M., Blondet, C., Bonardel, G., Le Stanc, E., Mantzarides, M., Foehrenbach, H., Pecking, A.-P., & Alberini, J.-L. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0563-6 · Cited by 196
Interaction of Organic Cations with a Newly Identified Plasma Membrane Monoamine Transporter
Engel, K., & Wang, J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016832 · Cited by 190 · cited 1×
“PMAT was originally identified as a monoamine transporter from the equilibrative nucleoside transporter (ENT) family, found predominantly in the brain and central nervous system [23, 24].”
BackgroundRole of Metformin Accumulation in Metformin-Associated Lactic Acidosis
Lalau, J. D., Lacroix, C., Compagnon, P., Cagny, B. D., Rigaud, J. P., Bleichner, G., Chauveau, P., Dulbecco, P., Guérin, C., Haegy, J. M., et al. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.779 · Cited by 185
Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S. F., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N. A., et al. (2009) · Diabetes · doi:10.2337/db08-0896 · Cited by 184 · cited 1×
“This is consistent with a report by our group (Zhou et al) on the Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) data, where we found no effect on the glycaemic response to metformin in a large population of patients with type 2 diabetes [31].”
ResultSelf-citationMigoya, E. M., Bergeron, R., Miller, J. L., Snyder, R. N. K., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.184 · Cited by 179 · cited 3×
“A study in mice reported that metformin increases the expression of precursor proteins such as preproglucagon and proglucagon in the large intestine, potentially increasing GLP-1 production and secretion [61].”
BackgroundBeysen, C., Murphy, E. J., Deines, K., Chan, M., Tsang, E., Glass, A., Turner, S. M., Protasio, J., Riiff, T., & Hellerstein, M. K. (2012) · Diabetologia · doi:10.1007/s00125-011-2382-3 · Cited by 163 · cited 1×
“In addition, as discussed previously, the alteration in bile acid absorption may result in increased GLP-1 secretion, in a similar way to that observed with bile acid sequestrants such as colesevelam [76, 77].”
ResultMulherin, A. J., Oh, A. H., Kim, H., Grieco, A., Lauffer, L. M., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1485 · Cited by 161 · cited 2×
“Whilst one study on L cell-like lines did not support a direct effect of metformin on L cells to mediate this effect [60], a more recent study has reported a direct effect of metformin on these cells, where an increase in the expression of the gene encoding proglucagon by metformin is mediated via…”
BackgroundResultEffect of metformin on bile salt circulation and intestinal motility in Type 2 diabetes mellitus
Scarpello, J. H. B., Hodgson, E., & Howlett, H. C. S. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199808)15:8<651::aid-dia628>3.0.co;2-a · Cited by 160 · cited 4×
“It has also been suggested that an increased luminal bile salt concentration would have an osmotic effect, which could lead to the diarrhoea associated with metformin treatment [72].”
BackgroundInfluentialGLUT2 Accumulation in Enterocyte Apical and Intracellular Membranes
Ait-Omar, A., Monteiro-Sepulveda, M., Poitou, C., Le Gall, M., Cotillard, A., Gilet, J., Garbin, K., Houllier, A., Château, D., Lacombe, A., et al. (2011) · Diabetes · doi:10.2337/db10-1740 · Cited by 159 · cited 2×
“Interestingly, fasting obese humans, unlike fasting lean individuals, have persistent GLUT2 abundance in the apical membrane, signifying dysregulation of glucose sensing and transfer [41].”
BackgroundInhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
Lindsay, J. R., Duffy, N. A., McKillop, A. M., Ardill, J., O'Harte, F. P. M., Flatt, P. R., & Bell, P. M. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01461.x · Cited by 158
Yi, F., Sun, J., Lim, G. E., Fantus, I. G., Brubaker, P. L., & Jin, T. (2008) · Endocrinology · doi:10.1210/en.2007-1142 · Cited by 157 · cited 4×
“…a direct effect of metformin on L cells to mediate this effect [60], a more recent study has reported a direct effect of metformin on these cells, where an increase in the expression of the gene encoding proglucagon by metformin is mediated via a β -catenin – TCF7L2-mediated mechanism [63, 65].”
BackgroundInfluentialMetformin interferes with bile acid homeostasis through AMPK-FXR crosstalk
Lien, F., Berthier, A., Bouchaert, E., Gheeraert, C., Alexandre, J., Porez, G., Prawitt, J., Dehondt, H., Ploton, M., Colin, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci68815 · Cited by 151 · cited 1×
“Metformin inhibits the farnesoid X receptor (FXR) via an AMPK-mediated mechanism, resulting in reduced sensing and ileal absorption of bile acids [66].”
BackgroundStepensky, D., Friedman, M., Raz, I., & Hoffman, A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.861 · Cited by 149
Importance of the intestine as a site of metformin‐stimulated glucose utilization
Bailey, C. J., Mynett, K. J., & Page, T. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb13128.x · Cited by 147
Self-citationWALKER, J., JIJON, H. B., DIAZ, H., SALEHI, P., CHURCHILL, T., & MADSEN, K. L. (2005) · Biochemical Journal · doi:10.1042/bj20040694 · Cited by 145 · cited 1×
“…apical membrane of rat jejunum [38]; a study assessing the response to 5 ′ -AMP-activated protein kinase (AMPK) activators (5-aminoimidazole-4-carboxamide ribonucleotide [AICAR] and metformin) suggests GLUT2 localisation to the apical membrane is mediated via rapid AMPK phosphorylation [38, 39].”
BackgroundEnhanced secretion of glucagon-like peptide 1 by biguanide compounds
Yasuda, N., Inoue, T., Nagakura, T., Yamazaki, K., Kira, K., Saeki, T., & Tanaka, I. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02565-2 · Cited by 137 · cited 1×
“First, metformin increases active GLP-1 levels in DPP4-deficient rats [59].”
BackgroundHan, T. K., Proctor, W. R., Costales, C., Cai, H., Everett, R., & Thakker, D. R. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220350 · Cited by 134 · cited 3×
“However, comparison of the expression of these transporters in Caco-2 cells vs human jejunum using western blot analysis revealed that the expression of all four proteins was significantly higher in Caco-2 cells, with the expression of CHT in human jejunum barely detectable [20].”
BackgroundResultMechanisms Underlying Saturable Intestinal Absorption of Metformin
Proctor, W. R., Bourdet, D. L., & Thakker, D. R. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.020180 · Cited by 133 · cited 2×
“…surface of enterocytes via bidirectional transporters, but that efflux across the basolateral surface of enterocytes is limited, resulting in the accumulation of metformin in the epithelium [16], possibly accounting for the greatly increased metformin concentration seen in these cells.”
BackgroundEffect of metformin on glucose metabolism in the splanchnic bed
Bailey, C. J., Wilcock, C., & Day, C. (1992) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1992.tb09093.x · Cited by 129 · cited 3×
“Several studies have attempted to localise the lactate production associated with metformin treatment [44 – 49].”
BackgroundSelf-citationEffect of altered gastric emptying and gastrointestinal motility on metformin absorption
Marathe, Wen, Y., Norton, J., Greene, D. S., Barbhaiya, R. H., & Wilding, I. R. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00264.x · Cited by 124 · cited 1×
“Absorption of immediate-release formulations of metformin is largely confined to the small intestine, with negligible absorption in the stomach or large intestine [4, 10, 11].”
BackgroundHeritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis
Zhou, K., Donnelly, L., Yang, J., Li, M., Deshmukh, H., Van Zuydam, N., Ahlqvist, E., Spencer, C. C., Groop, L., Morris, A. D., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70050-6 · Cited by 124 · cited 1×
“There are likely to be a number of factors to account for this variability in efficacy, for example, our group (Zhou et al) recently established that the glycaemic response to metformin is moderately heritable, i.e. due in part to genetic variation [8].”
BackgroundSelf-citationFirneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012226 · Cited by 121 · cited 1×
“However, in vitro studies have yet to find a direct effect of metformin on the activity of DPP4 [58], suggesting that any effect of metformin on DPP4 activity may be indirect, possibly by influencing hepatic production of DPP4 [56, 64].”
BackgroundGreen, B. D., Irwin, N., Duffy, N. A., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.043 · Cited by 121
Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1
Hinke, S. A., Kühn‐Wache, K., Hoffmann, T., Pederson, R. A., McIntosh, C. H. S., & Demuth, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6607 · Cited by 110 · cited 1×
“However, in vitro studies have yet to find a direct effect of metformin on the activity of DPP4 [58], suggesting that any effect of metformin on DPP4 activity may be indirect, possibly by influencing hepatic production of DPP4 [56, 64].”
BackgroundPénicaud, L., Hitier, Y., Ferré, P., & Girard, J. (1989) · Biochemical Journal · doi:10.1042/bj2620881 · Cited by 105
Han, T. K., Everett, R., Proctor, W. R., Ng, C. M., Costales, C., Brouwer, K. L. R., & Thakker, D. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084517 · Cited by 103 · cited 1×
“Although initial reports localised OCT1 to the basolateral membrane [19], more recent reports place OCT1 on the apical surface of intestinal epithelial cells [20, 21].”
ResultA Comprehensive Review of Drug–Drug Interactions with Metformin
Stage, T. B., Brøsen, K., & Christensen, M. M. H. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0270-6 · Cited by 97 · cited 1×
“There are well-documented, relatively common loss-of-function variants in human OCT1, and genetic variation in OCT1 has been investigated by a number of groups in relation to pharmacokinetics, efficacy and GI intolerance [7, 26 – 29].”
BackgroundVardarli, I., Arndt, E., Deacon, C. F., Holst, J. J., & Nauck, M. A. (2014) · Diabetes · doi:10.2337/db13-0805 · Cited by 92
Metformin-induced regulation of the intestinal D-glucose transporters.
Sakar, Y., Meddah, B., Faouzi, M. A., Cherrah, Y., Bado, A., & Ducroc, R. A. (2010) · PubMed · Cited by 89
Lee, N., Duan, H., Hebert, M. F., Liang, C. J., Rice, K. M., & Wang, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.570564 · Cited by 85
Alteration of bile acid metabolism and vitamin-B12-absorption in diabetics on biguanides
Caspary, W. F., Zavada, I., Reimold, W., Deuticke, U., Emrich, D., & Willms, B. (1977) · Diabetologia · doi:10.1007/bf01219698 · Cited by 82
Burton, J. H., Johnson, M., Johnson, J., Hsia, D. S., Greenway, F. L., & Heiman, M. L. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815577425 · Cited by 79 · cited 1×
“Burton et al carried out a small open-label crossover study using a GI microbiome modulator (GIMM) or placebo in conjunction with metformin in metformin-intolerant patients with type 2 diabetes [87].”
BackgroundWu, T., Thazhath, S. S., Bound, M. J., Jones, K. L., Horowitz, M., & Rayner, C. K. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.08.004 · Cited by 74
The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26
Koehler, M. R., Wissinger, B., Gorboulev, V., Koepsell, H., & Schmid, M. (1997) · Cytogenetic and Genome Research · doi:10.1159/000134720 · Cited by 74 · cited 1×
“OCTs are members of solute carrier family 22 (SLC22), initially described in 1994, and encoded on chromosome 6q26 [17].”
BackgroundEffects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors
Cubeddu, L. X., Bönisch, H., Göthert, M., Molderings, G. J., Racké, K., Ramadori, G. P., Miller, K. J., & Schwörer, H. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900152 · Cited by 67
Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling
Kim, M.-H., Jee, J.-H., Park, S., Lee, M.-S., Kim, K.-W., & Lee, M.-K. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0381 · Cited by 66 · cited 1×
“Whilst one study on L cell-like lines did not support a direct effect of metformin on L cells to mediate this effect [60], a more recent study has reported a direct effect of metformin on these cells, where an increase in the expression of the gene encoding proglucagon by metformin is mediated via a β-catenin–TCF7L2-m…”
ResultFadini, G. P., Albiero, M., Menegazzo, L., de Kreutzenberg, S. V., & Avogaro, A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01550.x · Cited by 65 · cited 1×
“Several mouse and human in vivo studies have reported a metformin-associated reduction in DPP4 activity [50 – 57].”
BackgroundOh, J.-R., Song, H., Chong, A. K. S., Ha, J., Jeong, S.-Y., Min, J., & Bom, H. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.10.4663 · Cited by 63 · cited 2×
“For this reason it is recommended that metformin be discontinued for at least 48 h prior to a PET-CT procedure/scan [33, 35].”
BackgroundDavis, T. M. E., Jackson, D., Davis, W. A., Bruce, D. G., & Chubb, P. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01423.x · Cited by 62 · cited 1×
“Observational data indicate that metformin causes a rise in fasting and average lactate levels [43], with an average increase (adjusted for plasma glucose and BMI) of 0.16 mmol/l compared with diet or sulfonylurea treatment.”
InfluentialSteady-State Pharmacokinetics of Metformin Is Independent of the OCT1 Genotype in Healthy Volunteers
Christensen, M. M. H., Højlund, K., Hother-Nielsen, O., Stage, T. B., Damkier, P., Beck-Nielsen, H., & Brøsen, K. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1853-8 · Cited by 62 · cited 1×
“Consistent with this interpretation, a recent study concluded that OCT1 variants with loss of function do not alter metformin concentrations in healthy volunteers titrated to 1 g/day of metformin [27].”
BackgroundDifferential effects of metformin on bile salt absorption from the jejunum and ileum
Carter, D., Howlett, H. C. S., Wiernsperger, N. F., & Bailey, C. J. (2003) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00252.x · Cited by 53 · cited 2×
“Bile acid absorption in the jejunum is a passive, non-saturable and concentration-dependent process, whereas ileal absorption is mainly an active process [73].”
BackgroundSelf-citationCuthbertson, J., Patterson, S., O'Harte, F. P. M., & Bell, P. M. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02748.x · Cited by 50
Pharmacogenetic Variation and Metformin Response
Chen, S., Zhou, J., Xi, M., Jia, Y., Wong, Y., Zhao, J., Ding, L., Zhang, J., & Wen, A. (2013) · Current Drug Metabolism · doi:10.2174/1389200214666131211153933 · Cited by 50 · cited 1×
“The impact of variants in PMAT [30] and SERT on these outcomes needs to be assessed.”
BackgroundPrediction and validation of enzyme and transporter off-targets for metformin
Yee, S. W., Lin, L., Merski, M., Keiser, M. J., Gupta, A., Zhang, Y., Chien, H.-C., Shoichet, B. K., & Giacomini, K. M. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9436-y · Cited by 49 · cited 2×
“As an alternative explanation, it could be that metformin uptake via SERT or OCT1 results in reduced serotonin transport and resultant GI side-effects [69].”
BackgroundThondam, S. K., Cross, A., Cuthbertson, D. J., Wilding, J. P., & Daousi, C. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03675.x · Cited by 43
New prolonged-release metformin improves gastrointestinal tolerability
Davidson, J., & Howlett, H. (2004) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514040040041101 · Cited by 38 · cited 1×
“On contact with fluid from the GI tract, the tablet swells, and the metformin is released as the polymer gradually breaks down [14].”
BackgroundZema, M. J. (2012) · Core evidence · doi:10.2147/ce.s26725 · Cited by 29 · cited 1×
“In addition, as discussed previously, the alteration in bile acid absorption may result in increased GLP-1 secretion, in a similar way to that observed with bile acid sequestrants such as colesevelam [76, 77].”
ResultDoes apical membrane GLUT2 have a role in intestinal glucose uptake?
Naftalin, R. J. (2014) · F1000Research · doi:10.12688/f1000research.5934.1 · Cited by 27 · cited 2×
“The mechanism whereby metformin increases gut glucose uptake and utilisation remains unclear [36 – 40].”
BackgroundEffects of metformin on bile salt transport by monolayers of human intestinal Caco‐2 cells
Carter, D., Howlett, H. C. S., Wiernsperger, N. F., & Bailey, C. J. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00223.x · Cited by 27 · cited 2×
“Several studies have demonstrated reduced absorption of bile acids in patients receiving metformin treatment and shown this to be a direct effect of metformin on enterocytes [65, 72 – 75].”
BackgroundSelf-citationMetformin and cancer: Technical and clinical implications for FDG-PET imaging
Capitanio, S., Marini, C., Sambuceti, G., & Morbelli, S. D. (2015) · World Journal of Radiology · doi:10.4329/wjr.v7.i3.57 · Cited by 16
(2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000105 · Cited by 8 · cited 1×
“glycaemic response to metformin in a clinical trial [28] was not confirmed in a recent re-analysis that took account of the baseline HbA1c level [29].”
Result
Cited by
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
“There are a number of putative mechanisms for how metformin could impact on glucose metabolism via actions on the intestines (reviewed in [40]).”
BackgroundSelf-citationWu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
Metformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
“Advances in pharmacogenomics may better inform responsiveness to metformin and effects on the gut microbiome, and animal studies have intriguingly noted anti-ageing effects of metformin [90, 91].”
BackgroundSelf-citationCellular and Molecular Mechanisms of Metformin Action
LaMoia, T. E., & Shulman, G. I. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa023 · Cited by 791
“…intolerance in ~5% of patients (76-78) In recent years, the clinical benefits of metformin have been linked to alterations in gut microbiome composition, intestinal glucose uptake, and hormone (eg, growth differentiation factor 15 [GDF15], glucagon-like peptide-1 [GLP-1]) secretion (44, 45, 79-82).”
BackgroundMetformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 699
Metadata
- Authors
- McCreight, L. J., Bailey, C. J., & Pearson, E. R.
- Affiliations
- University of Dundee (GB)
- Aston University (GB)
- Corresponding author
- Pearson, Ewan R.
- Venue
- Diabetologia
- Published
- 2016-01-16
- Volume
- 59
- Issue
- 3
- Pages
- 426-435
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC4742508
- OpenAlex
- W2255443535
- Cited by
- 733
- References
- 89
- Citations by year
- 2026: 53 · 2025: 75 · 2024: 83 · 2023: 97 · 2022: 73 · 2021: 79 · 2020: 88 · 2019: 48 · 2018: 62 · 2017: 50 · 2016: 25
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Aston Publications Explorer (Aston University) (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, cc-by)
- Funders
- Wellcome Trust (102820/Z/13/Z, 102820)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- metformin, gastrointestinal tract, type 2 diabetes, intestinal glucose absorption, lactic acid production, glucagon-like peptide-1, bile acids, gut microbiota, metformin intolerance, adverse drug reactions, glycemic control
- MeSH terms
- Humans, Metformin, Gastrointestinal Tract, Glucagon-Like Peptide 1, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.